Top Qs
Timeline
Chat
Perspective
Maridebart cafraglutide
Experimental medication From Wikipedia, the free encyclopedia
Remove ads
Maridebart cafraglutide (also known as MariTide;[1] developmental name AMG 133) is an investigational drug developed by Amgen for the treatment of obesity. It is an agonist of the GLP-1 receptor (GLP-1R) and an antagonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR). Namely, MariTide consists of a monoclonal antibody against GIPR conjugated to two peptidic GLP-1R agonist molecules via amino acid linkers.[2] In a preliminary trial, AMG 133 resulted in a 14.5 percent weight loss after 12 weeks at the highest dose tested.[3][4][5]
Remove ads
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads